Company Overview
| Stock Name | Viva Biotech |
|---|---|
| Stock Code | 01873 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 經營基於結構的新藥發現技術平台,為全球生物科技及製藥客戶的臨床前階段創新藥物開發提供藥物發現服務,涵蓋靶標蛋白表達與結構研究、藥物篩選、先導化合物優化至確定臨床候選化合物。 |
| Listing Date | 2019-05-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區愛迪生路334號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | vivabiotech.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 4.41 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-04-25 to 2019-04-30 |
| Global Offering Shares | 345,000,000 shares |
| HK Public Offer Shares (Initial) | 34,500,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 310,500,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,500,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 23.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,521,450,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 3.27B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +197% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 96,492 | 148,245 | 210,033 |
| Cost of sales | -42,349 | -62,056 | -104,576 |
| Gross profit | 54,143 | 86,189 | 105,457 |
| Other income and gains, net | 7,088 | 6,412 | 4,671 |
| Selling and distribution expenses | -1,392 | -2,017 | -3,925 |
| Administrative expenses | -12,827 | -15,228 | -25,576 |
| Net finance costs | -203 | -853 | -557 |
| Share of associates and JVs | -3,403 | -4,112 | -3,246 |
| Profit before tax | 28,420 | 86,811 | 105,861 |
| Income tax expense | -3,947 | -10,551 | -15,311 |
| Profit for the year | 24,473 | 76,260 | 90,550 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 13,425 | 29,766 | 155,554 |
| Trade and bills receivables | 24,064 | 36,875 | 68,410 |
| Inventories | 1,013 | 3,323 | 4,900 |
| Total current assets | 65,164 | 83,447 | 241,170 |
| Total assets | 101,821 | 202,402 | 529,339 |
| Total current liabilities | 16,320 | 36,991 | 42,462 |
| Total liabilities | 25,319 | 49,640 | 277,897 |
| Total equity | 76,502 | 152,762 | 251,442 |
| Interest-bearing borrowings | 3,506 | 14,945 | 2,362 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Net cash from operating activities | 21,118 | 27,891 | 12,110 |
| Net cash from investing activities | -19,589 | -9,762 | -69,949 |
| Net cash from financing activities | -741 | -849 | 179,479 |
| Net increase in cash | 788 | 17,280 | 121,640 |
| Depreciation of PP&E | 3,782 | 5,501 | 9,548 |
| Purchase of PP&E | -7,341 | -18,923 | -46,903 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 4.42 |
|---|---|
| First Day Open | HK$ 4.51 |
| First Day Change | 0.23% |
| First Day Volume | 155638000.0 |
| First Day Turnover | 704407000.0 |
| Use of Proceeds | 1、約30%或411.8百萬港元將用于擴大EFS模式,將更多前景可觀的中國及海外生物科技初創公司加入我們的孵化投資企業組合;
2、約30%或411.8百萬港元將用于建立商業及研究制作能力及生物CMO及化學CMO的能力;
3、約10%或137.3百萬港元將用于按擴充計劃購置實驗室設備及物料;
4、約10%或137.3百萬港元將用于招聘、培訓及保留生物及化學藥物研發人員;
5、約10%或137.3百萬港元將用于擴充CMO業務,可能包括收購新技術、業務或服務,及╱或與第三方建立戰略聯盟;
6、約10%或137.3百萬港元將用作我們的一般公司及營運資金。 |
Underwriting Syndicate
Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (3)
Joint Bookrunners (6)
Joint Lead Managers (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Nomura International (Hong Kong) Limited CE AAF742
BOCI ASIA LIMITED CE AET863
China Renaissance Securities (Hong Kong) Limited CE AZX839
海通国际证券有限公司 CE AAF806
Daiwa Capital Markets Hong Kong Limited CE AAB639
FIRST SHANGHAI SECURITIES LIMITED CE ABV488
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Gaotejia Investment Management Co., Ltd | 94,111,605 HKD | — | 6.19% | — | 6 months | 2019-11-09 |
| 2 | 深圳市高特佳睿宝投资合伙企业(有限合伙) | 141,168,510 HKD | — | 9.28% | — | 6 months | 2019-11-09 |
| 3 | 中国医药投资有限公司 | 116,790,030 HKD | — | 7.68% | — | 6 months | 2019-11-09 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 毛晨 | — |
| Company Secretary | 費曉玉、周慶齡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 毛先生持股23.46%、毛女士持股21.11%、吳炯先生持股17.05%、Zhang and Sons持股10.63%、Fenghe Harvest持股10.32%、華先生持股8.26% |
|---|




